Serotonergic system modulation holds promise for L‐DOPA‐induced dyskinesias in hemiparkinsonian rats

Simple item page
dc.contributor.authorFarajdokht, Fereshteh
dc.contributor.authorSadigh-Eteghad, Saeed
dc.contributor.authorMajdi, Alireza
dc.contributor.authorPashazadeh, Fariba
dc.contributor.authorVatandoust, Seyyed Mehdi
dc.contributor.authorZiaee, Mojtaba
dc.contributor.authorSafari, Fatemeh
dc.contributor.authorKarimi, Pouran
dc.contributor.authorMahmoudi, Javad
dc.date.accessioned2020-12-16T14:47:47Z
dc.date.available2020-12-16T14:47:47Z
dc.date.issued2020-03-02
dc.description.abstractThe alleged effects of serotonergic agents in alleviating levodopa-induced dyskinesias (LIDs) in parkinsonian patients are debatable. To this end, we systematically reviewed the serotonergic agents used for the treatment of LIDs in a 6-hydroxydopamine model of Parkinson’s disease in rats. We searched MEDLINE via PubMed, Embase, Google Scholar, and Proquest for entries no later than March 2018, and restricted the search to publications on serotonergic agents used for the treatment of LIDs in hemiparkinsonian rats. The initial search yielded 447 citations, of which 49 articles and one conference paper met our inclusion criteria. The results revealed ten different categories of serotonergic agents, including but not limited to 5-HT1A/BR agonists, 5-HT2AR antagonists, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitor (SNRIs), and tricyclic antidepressants (TCAs), all of which improved LIDs without imposing considerable adverse effects. Although there is promising evidence regarding the role of these agents in relieving LIDs in hemiparkinsonian rats, further studies are needed for the enlightenment of hidden aspect of these molecules in terms of mechanisms and outcomes. Given this, improving the quality of the pre-clinical studies and designing appropriate clinical trials will help fill the bench-to-bedside gap.en
dc.identifier.citationFarajdokht, F., Sadigh-Eteghad, S., Majdi, A., Pashazadeh, F., Vatandoust, S. M., Ziaee, M., Safari, F., Karimi, P., & Mahmoudi, J. (2020). Serotonergic system modulation holds promise for L‐DOPA‐induced dyskinesias in hemiparkinsonian rats: A systematic review. EXCLI Journal, 19, 268-295. https://doi.org/10.17179/excli2020-1024de
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/39902
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-21792
dc.language.isoen
dc.publisherIfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmundde
dc.relation.ispartofseriesEXCLI Journal;Vol. 19. 2020, pp. 268-295
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectL-DOPAen
dc.subjectLevodopa-induced dyskinesiasen
dc.subject6-hydroxydopamineen
dc.subjectRaten
dc.subjectSerotonergic systemen
dc.subject.ddc610
dc.titleSerotonergic system modulation holds promise for L‐DOPA‐induced dyskinesias in hemiparkinsonian ratsen
dc.title.alternativeA systematic reviewen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.zdberstkatid2132560-1
eldorado.dnb.zdberstkatidtrue
eldorado.identifier.urlhttps://www.excli.de/index.php/excli/article/view/1908

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mahmoudi_02032020_proof.pdf
Size:
374.79 KB
Format:
Adobe Portable Document Format
Description:
DNB
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Review Articles 2020